中国临床药学杂志2024，Vol.33Issue(5)：354-361,8.DOI:10.19577/j.1007-4406.2024.05.006
达格列净对早期糖尿病肾病患者肾脏保护作用的Meta分析
Meta analysis of the protective effect of dapagliflozin on early diabetic nephropathy
摘要
Abstract
AIM To explore the renal protection effect of dapagliflozin on early diabetic nephropathy patients,so as to provide reference for clinical practice.METHODS Chinese databases such as CNKI,Wanfang data,VIP,CBM,and English databases such as Pubmed,Embase,Cochrane were searched.The search period was from the establishment of the database to June 2023.Randomized controlled studies of dapagliflozin on renal protection in patients with early diabetic nephropathy were queried.Literature screening,data extraction and study quality evaluation were conducted.Patients were divided into obvervation group and control group,and Meta-analysis was performed using RevMan 5.4.RESULTS A total of 1975 patients were included in 22 studies.Meta-analysis showed that compared with the control group,the difference in urine albumin-creatine ratio(P＜0.000 1),the difference in microalbunminuria(P＜0.000 1),the difference in serum uric acid(△UA,P=0.002),the difference in human macrophage chemoattractant protein-1(P＜0.000 01),the difference in interleukin-6(P=0.000 02),and the difference in transforming growth factor-alpha(P＜0.000 01)in the observation group were all higher than those in the control group.However,differences in urinary albumin excretion rate,24 h-uridine triphosphate,glomerular filtration rate,serum creatinine,and blood urea nitrogen between 2 groups were not statistically significant(P＞0.05).CONCLUSION Dapagliflozin has shown a certain protective effect on early diabetic nephropathy.However,given the limitations of the inclusion study,it still needs to be verified by large-scale randomized controlled clinical studies with rigorous design.关键词
达格列净/早期糖尿病肾病/Meta分析Key words
dapagliflozin/early diabetes nephropathy/Meta-analysis分类
社会科学引用本文复制引用
徐锦龙,姚莉莉,马卫成,唐梓椋,李娇..达格列净对早期糖尿病肾病患者肾脏保护作用的Meta分析[J].中国临床药学杂志,2024,33(5):354-361,8.基金项目
浙江省药学会医院药学专项基金项目(编号2018ZYY38) （编号2018ZYY38）
